Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919258 | 0.96 | LMNA (0.34) | CYP2C9POLBMAPTTHRBLMNA | |
| SCHEMBL2916555 | 0.96 | LMNA (0.34) | CYP2C9POLBMAPTTHRBLMNA | |
| SCHEMBL2923459 | 0.91 | CYP2C9 (0.34) | CYP2C9POLBRORCRENCASP3 | |
| SCHEMBL2923505 | 0.91 | CYP2C9 (0.34) | CYP2C9POLBRORCRENCASP3 | |
| SCHEMBL2924531 | 0.90 | CYP2C9 (0.33) | CYP2C9POLBRORCRENCASP3 | |
| SCHEMBL2923447 | 0.89 | CYP2C9 (0.34) | CYP2C9POLBRORCRENCASP3 | |
| SCHEMBL2922614 | 0.89 | FKBP1A (0.34) | CYP2C9POLBMAPTLMNASMN1; SMN2 | |
| SCHEMBL2922339 | 0.88 | FKBP1A (0.36) | CYP2C9POLBRORCRENCASP3 | |
| SCHEMBL2921908 | 0.88 | CYP2C9 (0.35) | CYP2C9POLBRORCRENCASP3 | |
| SCHEMBL2924719 | 0.88 | CYP2C9 (0.35) | CYP2C9POLBRORCRENCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | CYP2C9 3835/4885POLB 2005/4885RORC 4757/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | CYP2C9 171/4885POLB 2217/4885RORC 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.